Yan Li
Concepts (342)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptors, Calcitriol | 31 | 2016 | 134 | 9.860 |
Why?
| Vitamin D | 20 | 2016 | 264 | 5.240 |
Why?
| Renin-Angiotensin System | 18 | 2015 | 133 | 4.710 |
Why?
| Calcitriol | 13 | 2013 | 181 | 3.400 |
Why?
| Diabetic Nephropathies | 9 | 2017 | 223 | 2.580 |
Why?
| Signal Transduction | 16 | 2017 | 3297 | 2.370 |
Why?
| Renin | 11 | 2012 | 76 | 2.230 |
Why?
| Gene Expression Regulation | 17 | 2015 | 1936 | 1.950 |
Why?
| Intestinal Mucosa | 7 | 2015 | 892 | 1.880 |
Why?
| Podocytes | 6 | 2013 | 26 | 1.770 |
Why?
| Colitis | 6 | 2015 | 248 | 1.770 |
Why?
| Epithelial Cells | 8 | 2015 | 627 | 1.750 |
Why?
| NF-kappa B | 9 | 2017 | 429 | 1.740 |
Why?
| Vitamins | 5 | 2010 | 74 | 1.620 |
Why?
| Mice | 42 | 2017 | 11119 | 1.530 |
Why?
| MicroRNAs | 5 | 2016 | 508 | 1.320 |
Why?
| Animals | 51 | 2017 | 26937 | 1.220 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 4 | 2010 | 99 | 1.210 |
Why?
| Losartan | 7 | 2010 | 46 | 1.190 |
Why?
| Inflammation | 7 | 2015 | 821 | 1.190 |
Why?
| Hyperglycemia | 3 | 2017 | 183 | 1.150 |
Why?
| Kidney | 8 | 2017 | 1232 | 1.120 |
Why?
| Mesangial Cells | 2 | 2017 | 7 | 1.090 |
Why?
| Kidney Diseases | 4 | 2013 | 421 | 1.070 |
Why?
| Diabetes Mellitus, Experimental | 4 | 2017 | 192 | 1.060 |
Why?
| Inflammatory Bowel Diseases | 3 | 2015 | 523 | 1.060 |
Why?
| Mice, Knockout | 16 | 2015 | 1954 | 1.030 |
Why?
| Tumor Necrosis Factor-alpha | 5 | 2015 | 693 | 1.030 |
Why?
| Epigenesis, Genetic | 2 | 2017 | 427 | 1.000 |
Why?
| Cyclic AMP | 2 | 2017 | 280 | 0.950 |
Why?
| Ergocalciferols | 3 | 2010 | 39 | 0.900 |
Why?
| Vitamin D Deficiency | 5 | 2013 | 105 | 0.850 |
Why?
| Glucose | 2 | 2017 | 624 | 0.850 |
Why?
| Promoter Regions, Genetic | 8 | 2017 | 942 | 0.770 |
Why?
| Energy Metabolism | 2 | 2011 | 265 | 0.720 |
Why?
| ATP Citrate (pro-S)-Lyase | 1 | 2017 | 3 | 0.700 |
Why?
| Mice, Inbred C57BL | 11 | 2015 | 3176 | 0.700 |
Why?
| Histones | 2 | 2017 | 308 | 0.680 |
Why?
| Macrophages | 4 | 2013 | 556 | 0.680 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 59 | 0.680 |
Why?
| Suppressor of Cytokine Signaling Proteins | 2 | 2013 | 19 | 0.660 |
Why?
| Calcium | 8 | 2016 | 1223 | 0.660 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 2017 | 97 | 0.650 |
Why?
| Receptor, Angiotensin, Type 2 | 1 | 2015 | 5 | 0.630 |
Why?
| Albuminuria | 3 | 2016 | 143 | 0.620 |
Why?
| Homeostasis | 6 | 2015 | 397 | 0.620 |
Why?
| Myosin-Light-Chain Kinase | 1 | 2015 | 40 | 0.610 |
Why?
| Adipocytes | 3 | 2011 | 156 | 0.580 |
Why?
| Cardiovascular Diseases | 2 | 2013 | 812 | 0.580 |
Why?
| Interleukin-18 | 2 | 2006 | 30 | 0.570 |
Why?
| Pulmonary Fibrosis | 1 | 2015 | 119 | 0.560 |
Why?
| Protein Processing, Post-Translational | 1 | 2017 | 376 | 0.560 |
Why?
| Interleukin-10 | 1 | 2015 | 157 | 0.550 |
Why?
| Receptor, TIE-2 | 1 | 2013 | 17 | 0.550 |
Why?
| Angiopoietin-2 | 1 | 2013 | 20 | 0.540 |
Why?
| Keratinocytes | 2 | 2006 | 134 | 0.530 |
Why?
| Kidney Glomerulus | 2 | 2013 | 118 | 0.520 |
Why?
| Acute Lung Injury | 1 | 2013 | 54 | 0.510 |
Why?
| Colon | 4 | 2015 | 502 | 0.510 |
Why?
| Angiotensin II | 5 | 2015 | 92 | 0.500 |
Why?
| Angiotensinogen | 2 | 2009 | 5 | 0.500 |
Why?
| Atherosclerosis | 2 | 2013 | 231 | 0.500 |
Why?
| Gastrointestinal Tract | 1 | 2015 | 191 | 0.490 |
Why?
| Toll-Like Receptors | 1 | 2013 | 92 | 0.480 |
Why?
| Colonic Neoplasms | 2 | 2014 | 559 | 0.480 |
Why?
| Mice, Transgenic | 5 | 2015 | 1553 | 0.480 |
Why?
| Receptors, LDL | 1 | 2012 | 67 | 0.470 |
Why?
| Vitamin D Response Element | 1 | 2011 | 1 | 0.470 |
Why?
| Juxtaglomerular Apparatus | 2 | 2008 | 2 | 0.460 |
Why?
| Blood Pressure | 3 | 2007 | 1196 | 0.440 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2010 | 37 | 0.440 |
Why?
| Bone Density Conservation Agents | 1 | 2011 | 48 | 0.440 |
Why?
| Inflammation Mediators | 4 | 2013 | 159 | 0.440 |
Why?
| Fatty Acids | 1 | 2011 | 146 | 0.430 |
Why?
| HCT116 Cells | 3 | 2015 | 148 | 0.420 |
Why?
| Antihypertensive Agents | 4 | 2012 | 573 | 0.410 |
Why?
| RNA, Messenger | 8 | 2014 | 1992 | 0.410 |
Why?
| Membrane Proteins | 3 | 2012 | 1207 | 0.400 |
Why?
| Hair Follicle | 2 | 2016 | 25 | 0.400 |
Why?
| Fibroblasts | 3 | 2010 | 727 | 0.400 |
Why?
| Alopecia | 2 | 2016 | 34 | 0.400 |
Why?
| Humans | 34 | 2016 | 83081 | 0.400 |
Why?
| Protective Agents | 1 | 2009 | 32 | 0.400 |
Why?
| Immunity, Innate | 1 | 2013 | 429 | 0.400 |
Why?
| Cells, Cultured | 7 | 2016 | 2969 | 0.390 |
Why?
| Polyuria | 1 | 2008 | 8 | 0.390 |
Why?
| Thirst | 1 | 2008 | 19 | 0.390 |
Why?
| Up-Regulation | 5 | 2017 | 712 | 0.380 |
Why?
| Renal Insufficiency, Chronic | 1 | 2013 | 289 | 0.380 |
Why?
| Hypertension | 5 | 2015 | 1207 | 0.360 |
Why?
| Dextran Sulfate | 3 | 2014 | 73 | 0.360 |
Why?
| Mitochondrial Proteins | 1 | 2009 | 118 | 0.350 |
Why?
| Diabetes Mellitus, Type 2 | 3 | 2016 | 1279 | 0.350 |
Why?
| Fibrosis | 3 | 2017 | 189 | 0.350 |
Why?
| Ion Channels | 1 | 2009 | 258 | 0.340 |
Why?
| Lipopolysaccharides | 3 | 2013 | 276 | 0.330 |
Why?
| Captopril | 2 | 2004 | 25 | 0.330 |
Why?
| Models, Biological | 5 | 2013 | 1797 | 0.330 |
Why?
| Nucleocytoplasmic Transport Proteins | 1 | 2006 | 12 | 0.320 |
Why?
| Sialoglycoproteins | 1 | 2006 | 35 | 0.320 |
Why?
| Interleukin-1 | 1 | 2006 | 74 | 0.320 |
Why?
| I-kappa B Proteins | 1 | 2006 | 55 | 0.320 |
Why?
| Enzyme Inhibitors | 3 | 2009 | 674 | 0.320 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2007 | 249 | 0.300 |
Why?
| Calcium, Dietary | 1 | 2005 | 69 | 0.300 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 923 | 0.290 |
Why?
| Phosphorylation | 3 | 2017 | 1155 | 0.290 |
Why?
| Acetylation | 2 | 2017 | 121 | 0.280 |
Why?
| Cell Line, Transformed | 2 | 2017 | 159 | 0.280 |
Why?
| Connective Tissue Growth Factor | 2 | 2017 | 16 | 0.280 |
Why?
| Sulfates | 1 | 2004 | 62 | 0.280 |
Why?
| Active Transport, Cell Nucleus | 2 | 2017 | 74 | 0.280 |
Why?
| Cell Line | 5 | 2013 | 2614 | 0.280 |
Why?
| Cardiomegaly | 1 | 2004 | 110 | 0.270 |
Why?
| Disease Progression | 3 | 2015 | 1470 | 0.270 |
Why?
| Cation Transport Proteins | 1 | 2004 | 60 | 0.270 |
Why?
| Symporters | 1 | 2004 | 101 | 0.270 |
Why?
| Obesity | 1 | 2011 | 966 | 0.270 |
Why?
| Fibronectins | 2 | 2017 | 95 | 0.260 |
Why?
| Gene Expression | 6 | 2009 | 1332 | 0.260 |
Why?
| Apoptosis | 4 | 2015 | 1774 | 0.250 |
Why?
| RNA Interference | 3 | 2017 | 378 | 0.250 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2003 | 80 | 0.250 |
Why?
| Time Factors | 5 | 2017 | 5497 | 0.240 |
Why?
| Caco-2 Cells | 2 | 2015 | 145 | 0.240 |
Why?
| Permeability | 2 | 2015 | 140 | 0.240 |
Why?
| Neoplasm Proteins | 1 | 2006 | 547 | 0.240 |
Why?
| Mice, Inbred DBA | 2 | 2012 | 196 | 0.220 |
Why?
| Fumarates | 2 | 2012 | 25 | 0.210 |
Why?
| Amides | 2 | 2012 | 61 | 0.210 |
Why?
| Tight Junctions | 2 | 2013 | 143 | 0.200 |
Why?
| Cytokines | 3 | 2015 | 749 | 0.200 |
Why?
| Oxidation-Reduction | 2 | 2011 | 379 | 0.200 |
Why?
| DNA, Complementary | 3 | 2004 | 409 | 0.190 |
Why?
| Drug Synergism | 2 | 2010 | 335 | 0.190 |
Why?
| Disease Models, Animal | 4 | 2010 | 2299 | 0.190 |
Why?
| Receptor, Angiotensin, Type 1 | 3 | 2009 | 20 | 0.190 |
Why?
| Cell Nucleus | 3 | 2015 | 587 | 0.180 |
Why?
| Acetyl Coenzyme A | 1 | 2017 | 6 | 0.180 |
Why?
| Mice, Mutant Strains | 2 | 2011 | 252 | 0.170 |
Why?
| Transforming Growth Factor beta3 | 1 | 2017 | 21 | 0.170 |
Why?
| Collagen Type IV | 1 | 2017 | 24 | 0.170 |
Why?
| Trinitrobenzenesulfonic Acid | 2 | 2015 | 17 | 0.170 |
Why?
| Citric Acid | 1 | 2017 | 53 | 0.170 |
Why?
| Gene Expression Profiling | 1 | 2003 | 1367 | 0.170 |
Why?
| Enzyme Activation | 2 | 2013 | 737 | 0.170 |
Why?
| Transforming Growth Factor beta1 | 1 | 2017 | 90 | 0.170 |
Why?
| Drug Therapy, Combination | 2 | 2010 | 990 | 0.160 |
Why?
| Thioctic Acid | 1 | 2016 | 1 | 0.160 |
Why?
| Finasteride | 1 | 2016 | 9 | 0.160 |
Why?
| 5-alpha Reductase Inhibitors | 1 | 2016 | 8 | 0.160 |
Why?
| Salts | 2 | 2008 | 16 | 0.160 |
Why?
| Carnitine | 1 | 2016 | 17 | 0.160 |
Why?
| Sterols | 1 | 2016 | 18 | 0.160 |
Why?
| Immunoenzyme Techniques | 2 | 2014 | 329 | 0.160 |
Why?
| Leukocytes, Mononuclear | 2 | 2016 | 191 | 0.160 |
Why?
| Endocrine System | 2 | 2015 | 15 | 0.150 |
Why?
| Parathyroid Hormone | 2 | 2008 | 238 | 0.150 |
Why?
| Androgens | 1 | 2016 | 154 | 0.150 |
Why?
| Peptide Hormones | 1 | 2015 | 29 | 0.150 |
Why?
| Prostatic Hyperplasia | 1 | 2016 | 86 | 0.150 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 74 | 0.150 |
Why?
| HT29 Cells | 1 | 2014 | 49 | 0.150 |
Why?
| Transfection | 1 | 2017 | 943 | 0.150 |
Why?
| DNA Primers | 3 | 2008 | 571 | 0.140 |
Why?
| Blotting, Western | 2 | 2014 | 831 | 0.140 |
Why?
| Phytotherapy | 1 | 2016 | 135 | 0.140 |
Why?
| Steroid Hydroxylases | 1 | 2013 | 14 | 0.130 |
Why?
| Tumor Cells, Cultured | 1 | 2015 | 1088 | 0.130 |
Why?
| Down-Regulation | 2 | 2016 | 520 | 0.130 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2013 | 131 | 0.130 |
Why?
| Base Sequence | 2 | 2010 | 2427 | 0.130 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 286 | 0.130 |
Why?
| Water-Electrolyte Balance | 2 | 2003 | 70 | 0.130 |
Why?
| Male | 10 | 2016 | 41844 | 0.130 |
Why?
| Capillary Permeability | 1 | 2013 | 135 | 0.130 |
Why?
| Bone and Bones | 2 | 2004 | 266 | 0.120 |
Why?
| Feedback, Physiological | 1 | 2013 | 65 | 0.120 |
Why?
| Proteinuria | 1 | 2013 | 114 | 0.120 |
Why?
| Hyperparathyroidism, Secondary | 1 | 2013 | 73 | 0.120 |
Why?
| Wnt Signaling Pathway | 1 | 2013 | 86 | 0.120 |
Why?
| Flow Cytometry | 1 | 2014 | 724 | 0.120 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2013 | 202 | 0.120 |
Why?
| Transcriptional Activation | 1 | 2013 | 287 | 0.120 |
Why?
| Gene Deletion | 1 | 2013 | 346 | 0.120 |
Why?
| Mediator Complex Subunit 1 | 1 | 2011 | 1 | 0.120 |
Why?
| Nuclear Proteins | 1 | 2017 | 695 | 0.120 |
Why?
| Lipolysis | 1 | 2011 | 23 | 0.120 |
Why?
| Retinoid X Receptors | 1 | 2011 | 40 | 0.120 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2011 | 26 | 0.120 |
Why?
| Phenotype | 2 | 2011 | 2285 | 0.120 |
Why?
| Biological Transport, Active | 1 | 2011 | 104 | 0.120 |
Why?
| Thermogenesis | 1 | 2011 | 24 | 0.120 |
Why?
| Hypersensitivity | 1 | 2013 | 140 | 0.120 |
Why?
| Cell Adhesion Molecules | 1 | 2012 | 166 | 0.110 |
Why?
| Myocardial Infarction | 1 | 2015 | 370 | 0.110 |
Why?
| RNA Polymerase II | 1 | 2011 | 55 | 0.110 |
Why?
| Rats | 3 | 2015 | 4349 | 0.110 |
Why?
| Tumor Suppressor Proteins | 1 | 2013 | 281 | 0.110 |
Why?
| Intestines | 1 | 2015 | 424 | 0.110 |
Why?
| Bone Marrow Cells | 1 | 2012 | 256 | 0.110 |
Why?
| Kidney Tubules | 1 | 2011 | 101 | 0.110 |
Why?
| Organ Specificity | 1 | 2011 | 260 | 0.110 |
Why?
| Aorta | 1 | 2012 | 302 | 0.110 |
Why?
| Endothelial Cells | 1 | 2013 | 402 | 0.110 |
Why?
| Angiotensin I | 1 | 2010 | 5 | 0.110 |
Why?
| Locomotion | 1 | 2011 | 112 | 0.110 |
Why?
| Blood Urea Nitrogen | 1 | 2010 | 48 | 0.110 |
Why?
| Receptors, Leptin | 1 | 2010 | 34 | 0.110 |
Why?
| Chemokine CCL2 | 1 | 2010 | 46 | 0.110 |
Why?
| Ultraviolet Rays | 1 | 2011 | 194 | 0.110 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 384 | 0.100 |
Why?
| Collagen Type I | 1 | 2010 | 65 | 0.100 |
Why?
| Cholesterol | 1 | 2012 | 438 | 0.100 |
Why?
| Glomerular Basement Membrane | 1 | 2009 | 6 | 0.100 |
Why?
| Case-Control Studies | 1 | 2014 | 1825 | 0.100 |
Why?
| Lipids | 1 | 2012 | 387 | 0.100 |
Why?
| RNA | 2 | 2004 | 511 | 0.100 |
Why?
| Renal Dialysis | 1 | 2013 | 378 | 0.100 |
Why?
| Risk | 1 | 2011 | 700 | 0.100 |
Why?
| Extracellular Matrix Proteins | 1 | 2010 | 130 | 0.100 |
Why?
| Female | 8 | 2016 | 44708 | 0.100 |
Why?
| Colorectal Neoplasms | 1 | 2016 | 854 | 0.100 |
Why?
| HEK293 Cells | 1 | 2011 | 642 | 0.100 |
Why?
| Streptozocin | 1 | 2008 | 56 | 0.100 |
Why?
| Creatinine | 1 | 2010 | 347 | 0.100 |
Why?
| RNA, Small Interfering | 2 | 2008 | 568 | 0.090 |
Why?
| Prevalence | 1 | 2013 | 1261 | 0.090 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 2008 | 68 | 0.090 |
Why?
| Cell Differentiation | 2 | 2008 | 1474 | 0.090 |
Why?
| Retinoblastoma-Like Protein p130 | 1 | 2008 | 6 | 0.090 |
Why?
| Drug Interactions | 1 | 2009 | 271 | 0.090 |
Why?
| Transforming Growth Factor beta | 1 | 2010 | 286 | 0.090 |
Why?
| Drug Combinations | 1 | 2008 | 245 | 0.090 |
Why?
| Oxygen Consumption | 1 | 2009 | 249 | 0.090 |
Why?
| Ulcer | 1 | 2007 | 28 | 0.090 |
Why?
| Vacuolar Proton-Translocating ATPases | 1 | 2007 | 17 | 0.090 |
Why?
| Homeodomain Proteins | 1 | 2012 | 546 | 0.090 |
Why?
| Sodium | 1 | 2009 | 344 | 0.090 |
Why?
| Transcription, Genetic | 1 | 2013 | 1167 | 0.090 |
Why?
| Electric Impedance | 1 | 2007 | 102 | 0.090 |
Why?
| Lung | 1 | 2013 | 1058 | 0.090 |
Why?
| Lipid Metabolism | 1 | 2009 | 209 | 0.090 |
Why?
| Cholecalciferol | 1 | 2007 | 36 | 0.090 |
Why?
| Response Elements | 1 | 2007 | 66 | 0.090 |
Why?
| Drug Design | 1 | 2007 | 120 | 0.080 |
Why?
| Severity of Illness Index | 2 | 2016 | 1777 | 0.080 |
Why?
| Molecular Structure | 1 | 2007 | 291 | 0.080 |
Why?
| B-Lymphocytes | 1 | 2012 | 793 | 0.080 |
Why?
| Adenoma, Oxyphilic | 1 | 2006 | 31 | 0.080 |
Why?
| Phorbol Esters | 1 | 2006 | 30 | 0.080 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 1 | 2006 | 9 | 0.080 |
Why?
| Ligands | 1 | 2007 | 425 | 0.080 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2011 | 543 | 0.080 |
Why?
| Receptors, Cell Surface | 1 | 2007 | 296 | 0.080 |
Why?
| Crohn Disease | 1 | 2012 | 714 | 0.080 |
Why?
| Kidney Failure, Chronic | 1 | 2011 | 513 | 0.080 |
Why?
| Interleukin-6 | 1 | 2006 | 236 | 0.080 |
Why?
| RNA Stability | 1 | 2006 | 90 | 0.080 |
Why?
| Colitis, Ulcerative | 1 | 2012 | 687 | 0.080 |
Why?
| Antibodies | 1 | 2007 | 370 | 0.080 |
Why?
| Pregnancy | 1 | 2012 | 2809 | 0.070 |
Why?
| T-Lymphocytes | 1 | 2012 | 1287 | 0.070 |
Why?
| African Americans | 1 | 2013 | 1168 | 0.070 |
Why?
| Protein Structure, Tertiary | 1 | 2007 | 766 | 0.070 |
Why?
| Rickets | 1 | 2004 | 6 | 0.070 |
Why?
| Wound Healing | 1 | 2007 | 350 | 0.070 |
Why?
| Atrial Natriuretic Factor | 1 | 2004 | 38 | 0.070 |
Why?
| Duodenum | 1 | 2005 | 104 | 0.070 |
Why?
| Chromatin | 1 | 2007 | 340 | 0.070 |
Why?
| Parathyroid Glands | 1 | 2004 | 82 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 1 | 2009 | 2100 | 0.070 |
Why?
| Blotting, Northern | 1 | 2004 | 272 | 0.070 |
Why?
| Glutathione | 1 | 2004 | 107 | 0.070 |
Why?
| Proteoglycans | 1 | 2004 | 125 | 0.070 |
Why?
| Cell Movement | 1 | 2007 | 743 | 0.070 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 123 | 0.070 |
Why?
| Weight Gain | 1 | 2004 | 138 | 0.070 |
Why?
| Peptides | 1 | 2007 | 638 | 0.070 |
Why?
| Eating | 1 | 2004 | 174 | 0.070 |
Why?
| Submandibular Gland | 1 | 2003 | 17 | 0.060 |
Why?
| Aldosterone | 1 | 2003 | 63 | 0.060 |
Why?
| Sodium, Dietary | 1 | 2002 | 11 | 0.060 |
Why?
| Drinking Behavior | 1 | 2002 | 14 | 0.060 |
Why?
| Keratin-14 | 1 | 2002 | 5 | 0.060 |
Why?
| Calcium Signaling | 1 | 2003 | 132 | 0.060 |
Why?
| Hypocalcemia | 1 | 2002 | 44 | 0.060 |
Why?
| Extracellular Matrix | 1 | 2004 | 229 | 0.060 |
Why?
| Keratins | 1 | 2002 | 72 | 0.060 |
Why?
| Carcinoma, Renal Cell | 1 | 2006 | 397 | 0.060 |
Why?
| Cloning, Molecular | 1 | 2003 | 680 | 0.060 |
Why?
| Neuropeptides | 1 | 2002 | 116 | 0.060 |
Why?
| Myocytes, Cardiac | 1 | 2004 | 249 | 0.060 |
Why?
| Models, Genetic | 1 | 2007 | 921 | 0.060 |
Why?
| Cell Adhesion | 1 | 2003 | 427 | 0.060 |
Why?
| Transgenes | 1 | 2002 | 182 | 0.060 |
Why?
| Water | 1 | 2003 | 261 | 0.060 |
Why?
| Protein Kinase C | 1 | 2002 | 300 | 0.060 |
Why?
| DNA | 1 | 2007 | 1300 | 0.060 |
Why?
| Kidney Neoplasms | 1 | 2006 | 588 | 0.050 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 702 | 0.050 |
Why?
| Mutation | 1 | 2011 | 3853 | 0.050 |
Why?
| Adenocarcinoma | 1 | 2007 | 1194 | 0.050 |
Why?
| Trans-Activators | 1 | 2002 | 446 | 0.050 |
Why?
| Skin | 1 | 2002 | 560 | 0.050 |
Why?
| Liver | 1 | 2004 | 1241 | 0.050 |
Why?
| Treatment Outcome | 1 | 2011 | 7886 | 0.050 |
Why?
| Immunohistochemistry | 1 | 2002 | 1819 | 0.040 |
Why?
| Chemoprevention | 1 | 2016 | 90 | 0.040 |
Why?
| Subcellular Fractions | 1 | 2015 | 100 | 0.040 |
Why?
| Cytoprotection | 1 | 2015 | 46 | 0.040 |
Why?
| Caspase 3 | 1 | 2015 | 175 | 0.040 |
Why?
| Adenoma | 1 | 2016 | 265 | 0.040 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 245 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 320 | 0.030 |
Why?
| Protein Transport | 1 | 2015 | 420 | 0.030 |
Why?
| Cell Cycle | 1 | 2015 | 520 | 0.030 |
Why?
| Microvilli | 1 | 2009 | 47 | 0.020 |
Why?
| Ion Transport | 1 | 2009 | 84 | 0.020 |
Why?
| Exocytosis | 1 | 2009 | 107 | 0.020 |
Why?
| Cell Proliferation | 1 | 2015 | 1611 | 0.020 |
Why?
| Genes, Reporter | 1 | 2009 | 268 | 0.020 |
Why?
| Cell Polarity | 1 | 2009 | 120 | 0.020 |
Why?
| Azo Compounds | 1 | 2008 | 16 | 0.020 |
Why?
| 3T3-L1 Cells | 1 | 2008 | 40 | 0.020 |
Why?
| 3' Untranslated Regions | 1 | 2008 | 90 | 0.020 |
Why?
| Luciferases | 1 | 2008 | 122 | 0.020 |
Why?
| Mice, Inbred A | 1 | 2007 | 34 | 0.020 |
Why?
| Interleukin-1beta | 1 | 2007 | 72 | 0.020 |
Why?
| Cyclooxygenase 2 | 1 | 2007 | 97 | 0.020 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 119 | 0.020 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2007 | 109 | 0.020 |
Why?
| MAP Kinase Signaling System | 1 | 2007 | 194 | 0.020 |
Why?
| Tissue Array Analysis | 1 | 2006 | 128 | 0.020 |
Why?
| Cell Division | 1 | 2007 | 749 | 0.020 |
Why?
| Aged | 2 | 2016 | 18483 | 0.020 |
Why?
| Anti-Inflammatory Agents | 1 | 2007 | 343 | 0.020 |
Why?
| Middle Aged | 2 | 2016 | 25586 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2006 | 1604 | 0.010 |
Why?
| Cell Line, Tumor | 1 | 2007 | 2422 | 0.010 |
Why?
| Adult | 1 | 2016 | 25955 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2006 | 6577 | 0.010 |
Why?
|
|
Li's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Physical Neighbors  People whose addresses are nearby this person. _
|